News & Updates

Show Multimedia Only

Low-fat vegan diet’s alkalizing effect linked to greater weight loss

12 Jul 2025 by

A low-fat vegan diet yields a significant reduction in dietary acid load compared with the Mediterranean diet, and this alkalizing effect is associated with weight loss in overweight adults, according to the results of a cross-over study.

Low-fat vegan diet’s alkalizing effect linked to greater weight loss

12 Jul 2025

Novel adaptor enhances care for patients on NIV

12 Jul 2025 by

A new tube and inhaler adaptor (TIA) has been developed to improve the management of patients receiving noninvasive ventilation (NIV), and this device can be used across diverse clinical settings.

Novel adaptor enhances care for patients on NIV

12 Jul 2025

Depression tied to increased mortality in IPF

12 Jul 2025

Patients with idiopathic pulmonary fibrosis (IPF) and comorbid depression are less likely to initiate antifibrotic treatment and thus face an increased risk of death, as reported in a study.

Depression tied to increased mortality in IPF

12 Jul 2025

CYP2C19 tied to voriconazole-related adverse reactions in kids

11 Jul 2025

Carriers of the CYP2C19 allele are at greater risk of voriconazole-induced thrombocytopenia and cholestasis, reports a Japan study.

CYP2C19 tied to voriconazole-related adverse reactions in kids

11 Jul 2025

Nerandomilast safe, effective in autoimmune disease-related PPF

11 Jul 2025 by

Treatment with nerandomilast demonstrates efficacy in slowing forced vital capacity (FVC) decline in patients with autoimmune interstitial lung disease (ILD) similar to that seen in the overall trial population, reveals a subgroup analysis of the FIBRONEER-ILD study.

Nerandomilast safe, effective in autoimmune disease-related PPF

11 Jul 2025

Vancomycin 50-mg/kg dosage helps achieve target AUCf24h

11 Jul 2025

An empirical dosage of approximately 50 mg/kg on the first day of vancomycin therapy is needed to achieve an area under the concentration-time curve (AUC) in the first 24 h (AUCf24h), suggests a study while noting the use of two-point sampling in Bayesian estimations to improve accuracy.

Vancomycin 50-mg/kg dosage helps achieve target AUCf24h

11 Jul 2025

Nerandomilast slows IPF progression in patients already on antifibrotic therapy

11 Jul 2025 by

The novel oral PDE4B* inhibitor nerandomilast slows the progression of idiopathic pulmonary fibrosis (IPF) in patients receiving antifibrotic treatment, as shown in the phase III FIBRONEER-IPF trial.

Nerandomilast slows IPF progression in patients already on antifibrotic therapy

11 Jul 2025

Ambroxol safe but fails to improve cognition in Parkinson’s disease dementia

11 Jul 2025

Treatment with ambroxol in patients with Parkinson’s disease dementia (PDD) is safe and well tolerated but falls short of improving cognition, according to a single-centre phase II study.

Ambroxol safe but fails to improve cognition in Parkinson’s disease dementia

11 Jul 2025

Nurulimab-prolgolimab superior to prolgolimab alone in metastatic melanoma

11 Jul 2025 by

First-line nurulimab and prolgolimab combination therapy demonstrated superior efficacy compared with prolgolimab monotherapy in patients with unresectable or metastatic melanoma, according to the OCTAVA trial presented at AACR 2025.

Nurulimab-prolgolimab superior to prolgolimab alone in metastatic melanoma

11 Jul 2025

Lorundrostat for uncontrolled hypertension hits efficacy, safety targets in phase III trial

10 Jul 2025 by

Twelve weeks of treatment with the aldosterone synthase inhibitor lorundrostat proved efficacious and safe for lowering blood pressure (BP) in adults with uncontrolled hypertension, including those who were resistant to treatment, according to the phase III Launch-HTN trial.

Lorundrostat for uncontrolled hypertension hits efficacy, safety targets in phase III trial

10 Jul 2025

News & Updates

Filter by Specialty:

Specialty:

Low-fat vegan diet’s alkalizing effect linked to greater weight loss

Low-fat vegan diet’s alkalizing effect linked to greater weight loss

Novel adaptor enhances care for patients on NIV

Novel adaptor enhances care for patients on NIV

Depression tied to increased mortality in IPF

Depression tied to increased mortality in IPF

CYP2C19 tied to voriconazole-related adverse reactions in kids

CYP2C19 tied to voriconazole-related adverse reactions in kids

Nerandomilast safe, effective in autoimmune disease-related PPF

Nerandomilast safe, effective in autoimmune disease-related PPF

Vancomycin 50-mg/kg dosage helps achieve target AUCf24h

Vancomycin 50-mg/kg dosage helps achieve target AUCf24h

Nerandomilast slows IPF progression in patients already on antifibrotic therapy

Nerandomilast slows IPF progression in patients already on antifibrotic therapy

Ambroxol safe but fails to improve cognition in Parkinson’s disease dementia

Ambroxol safe but fails to improve cognition in Parkinson’s disease dementia

Nurulimab-prolgolimab superior to prolgolimab alone in metastatic melanoma

Nurulimab-prolgolimab superior to prolgolimab alone in metastatic melanoma

Lorundrostat for uncontrolled hypertension hits efficacy, safety targets in phase III trial

Lorundrostat for uncontrolled hypertension hits efficacy, safety targets in phase III trial